(Q35571833)

8 August 2017

title

A study of interval breast cancer within the NHS breast screening programme (English)

1 reference

8 August 2017

Cowan WK

1

1 reference

8 August 2017

Angus B

2

1 reference

8 August 2017

Gray JC

3

1 reference

8 August 2017

Lunt LG

4

1 reference

8 August 2017

al-Tamimi SR

5

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

Journal of Clinical Pathology

8 August 2017

published in

1 reference

8 August 2017

volume

53

1 reference

8 August 2017

issue

2

1 reference

8 August 2017

page(s)

140-146

1 reference

Steroid hormone receptors in breast cancer management

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Routinely available indicators of prognosis in breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Expression of metastasis-associated genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to disease progression.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Survival rates from interval cancer in NHS breast screening programme

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Rate and classification of interval cancers in the breast screening programme

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Monitoring interval cancers in breast screening programmes: the east Anglian experience. Quality Assurance Management Group of the East Anglian Breast Screening Programme

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Screening interval breast cancers: mammographic features and prognosis factors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Interval breast cancers in the Screening Mammography Program of British Columbia: analysis and classification

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Interval breast cancers are not biologically distinct--just more difficult to diagnose

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Is the three year breast screening interval too long? Occurrence of interval cancers in NHS breast screening programme's north western region

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

The clinical significance of p53 aberrations in human tumours

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Classifying interval cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

A prognostic index in primary breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Interval breast cancer: a more aggressive subset of breast neoplasias.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Survival in breast cancer diagnosed between mammographic screening examinations

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

The occurrence of interval cancers in the Nijmegen screening programme

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

The biology and natural history of breast cancer from the screening perspective

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Comparative pathology of breast cancer in a randomised trial of screening

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Breast screening, prognostic factors and survival – results from the Swedish two county study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

Interval cancer and survival in a randomized breast cancer screening trial in Stockholm

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1763287

An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth-regulated cross-reacting species p170

12 July 2018

1 reference

12 December 2020

Assessment of malignancy potential in so-called interval mammary carcinomas

1 reference

12 December 2020

Topographic criteria in the diagnosis of tumor emboli in intramammary lymphatics

1 reference

12 December 2020

The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases

1 reference

12 December 2020

Survival in interval breast cancer in the DOM screening programme

1 reference

12 December 2020

Interval carcinomas of the breast: a group with intermediate outcome

1 reference

12 December 2020

The pathological and biological nature of screen-detected breast carcinomas: a morphological and immunohistochemical study

1 reference

12 December 2020

Interval breast cancers in the NHS Breast Screening Programme: does the current definition exclude too many?

1 reference

12 December 2020

Ten- to fourteen-year effect of screening on breast cancer mortality

1 reference

12 December 2020

Identifiers

DOI

10.1136/JCP.53.2.140

1 reference

8 August 2017

1 reference

8 August 2017

1 reference